Gina Tomaine

News

Chemotherapy Plus Ponatinib Followed by Transplant Well-Tolerated in Adults With Philadelphia–Positive ALL

10/18/2022

The combination of chemotherapy with ponatinib followed by alloHSCT is well-tolerated in adults with Philadelphia chromosome–positive acute lymphoblastic leukemia, according to a phase 2 trial.

The combination of chemotherapy...

10/18/2022

Oncology

News

Ruxolitinib Shows Promise as a Safe, Effective Treatment for Steroid-Refractory GVHD

08/10/2022

Gina Tomaine ;

Ruxolitinib is a potentially effective and safe treatment for patients with steroid-refractory GVHD, according to findings from a systematic review and meta-analysis.

Ruxolitinib is a potentially...

08/10/2022

Oncology

News

Splenectomy Can Be Delayed in Transfusion-Dependent Thalassemia With Appropriate Chelation Therapy

09/22/2022

Gina Tomaine ;

Findings from a 30-year single-institution analysis reveal splenectomy can be delayed with appropriate chelation therapy in patients with transfusion-dependent thalassemia.

Findings from a 30-year...

09/22/2022

Oncology

News

Novel, Minimally Invasive Test Detects Higher Frequency of EZH2 Mutations in Follicular Lymphoma

11/14/2022

Gina Tomaine ;

Parallel testing of both tissue and liquid biopsy samples detects a higher frequency of EZH2 mutations in patients with follicular lymphoma, with significant clinical implications, according to a recent study.

Parallel testing of both tissue...

11/14/2022

Oncology

News

Busulfan Plus Cyclophosphamide vs Total Body Irradiation Plus Cyclophosphamide for ALL

09/20/2022

Gina Tomaine ;

Busulfan plus cyclophosphamide demonstrated noninferior efficiency and safety compared with total body irradiation plus cyclophosphamide for adult patients with standard-risk B-cell ALL in a phase 3 trial.

Busulfan plus cyclophosphamide...

09/20/2022

Oncology

News

Transfusion Burden Decrease, Hemoglobin Increase With Luspatercept vs Epoetin Alfa Treatment for ESA‑Naive Patients With Transfusion‑Dependent Lower‑Risk MDS

09/08/2023

Gina Tomaine ;

Luspatercept demonstrated multiple clinical benefits for ESA-naive patients with transfusion-dependent lower-risk MDS, including hemoglobin increases and transfusion-burden decreases, according to research presented at the SOHO 2023 Annual...

Luspatercept demonstrated...

09/08/2023

Oncology

News

Fixed Duration Venetoclax Plus Rituximab Provides Long-Term Benefit vs Bendamustine Plus Rituximab in CLL

11/15/2022

Gina Tomaine ;

Benefits associated with venetoclax-rituximab on the phase 3 MURANO trial were maintained at 3 years following treatment cessation in patients with relapsed/refractory CLL, according to an update published in Blood.

Benefits associated with...

11/15/2022

Oncology

News

Brentuximab Vedotin Plus AVD Demonstrates Efficacy, Safety in Hodgkin Lymphoma: BREACH Trial

08/17/2022

Gina Tomaine ;

For patients with early stage unfavorable Hodgkin lymphoma, brentuximab vedotin combined with AVD was associated with an improved rate of PET negativity vs standard ABVD in a phase 2 trial.

For patients with early stage...

08/17/2022

Oncology

News

Odronextamab Demonstrates Promising Safety, Response in R/R Non-Hodgkin Lymphoma

11/17/2022

Gina Tomaine ;

CD20-CD3 bispecific antibody odronextamab showed a manageable safety profile and encouraging preliminary activity in heavily pretreated patients with B-cell non-Hodgkin lymphoma, according to a recent phase 1 study.

CD20-CD3 bispecific antibody...

11/17/2022

Oncology

FDA Alerts

FDA Grants Approval to Ribociclib With Aromatase Inhibitor and Letrozole Co-Pack for Adjuvant Treatment of HR-Positive HER2-Negative High-Risk Breast Cancer

09/17/2024

Gina Tomaine ;

On September 17, 2024, the FDA approved ribociclib with an aromatase inhibitor as well as a ribociclib and letrozole co-pack for the adjuvant treatment of adults with hormone receptor-positive, HER2-negative stage II and III early breast...

On September 17, 2024, the FDA...

09/17/2024

Oncology